COVID-19 Mortality Risk Factors in Kidney Transplant Recipients Identified
Coinfection increased mortality risk among kidney transplant recipients with COVID-19, a study found.
Coinfection increased mortality risk among kidney transplant recipients with COVID-19, a study found.
The study evaluated Paxlovid in both vaccinated and unvaccinated patients with COVID-19 at standard risk for progressing to severe disease.
Concise drug information for molnupiravir and Paxlovid; the FDA granted Emergency Use to both oral antiviral therapies.
Findings demonstrated a 25-fold increase in neutralizing antibody titers in individuals who received the third dose.
Livtencity is indicated for posttransplant CMV that does not respond to available antiviral treatments
The CDC is recommending that health care providers take a travel history for all suspected and confirmed cases of COVID-19.
AZD7442 is a combination of 2 long-acting monoclonal antibodies, tixagevimab and cilgavimab, derived from B-cells donated by convalescent patients who were infected with the SARS-CoV-2 virus.
Maribavir is an orally bioavailable anti-CMV compound that targets and inhibits the UL97 protein kinase and its natural substrates.
Posoleucel is being investigated for the treatment and prevention of serious diseases caused by 6 viral pathogens.
The randomized, double-blind, placebo-controlled, multicenter PROVENT trial included 5197 participants aged 18 years and older who would benefit from AZD7442.